药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tazarotene
Solifenacin
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Arsenic trioxide.
Tazarotene
Ajmaline
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Arsenic trioxide.
Tazarotene
Methotrimeprazine
The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Arsenic trioxide.
Tazarotene
Arformoterol
The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Arsenic trioxide.
Tazarotene
Posaconazole
The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Arsenic trioxide.
Tazarotene
Lapatinib
The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Arsenic trioxide.
Tazarotene
Alimemazine
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Arsenic trioxide.
Tazarotene
Chlorprothixene
The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Arsenic trioxide.
Tazarotene
Sevoflurane
The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Arsenic trioxide.
Tazarotene
Metoclopramide
The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Arsenic trioxide.
Tazarotene
Encainide
The risk or severity of QTc prolongation can be increased when Encainide is combined with Arsenic trioxide.
Tazarotene
Desflurane
The risk or severity of QTc prolongation can be increased when Desflurane is combined with Arsenic trioxide.
Tazarotene
Cyclizine
The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Arsenic trioxide.
Tazarotene
Orphenadrine
The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Arsenic trioxide.
Tazarotene
Bretylium
The risk or severity of QTc prolongation can be increased when Bretylium is combined with Arsenic trioxide.
Tazarotene
Levocabastine
The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Arsenic trioxide.
Tazarotene
Perhexiline
The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Arsenic trioxide.
Tazarotene
Mequitazine
The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Arsenic trioxide.
Tazarotene
Gatifloxacin
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Arsenic trioxide.
Tazarotene
Tolterodine
The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Arsenic trioxide.